Generation Bio Co. (NASDAQ:GBIO) Short Interest Up 195.5% in August

Generation Bio Co. (NASDAQ:GBIO) was the target of a significant growth in short interest in August. As of August 15th, there was short interest totaling 290,800 shares, agrowthof195.5% from the July 31st total of 98,400 shares. Based on an average daily trading volume, of 348,700 shares, the days-to-cover ratio is currently 0.8 days. Currently,6.3% of the company’s shares are sold short. Currently,6.3% of the company’s shares are sold short. Based on an average daily trading volume, of 348,700 shares, the days-to-cover ratio is currently 0.8 days.

Generation Bio Stock Up 3.6%

Shares of GBIO stock opened at $5.99 on Friday. The stock’s 50-day moving average price is $4.88 and its 200 day moving average price is $4.49. Generation Bio has a 52-week low of $3.00 and a 52-week high of $29.10. The stock has a market capitalization of $40.37 million, a PE ratio of -0.55 and a beta of 2.48.

Generation Bio (NASDAQ:GBIO) last released its earnings results on Tuesday, August 12th. The company reported ($3.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.80) by ($0.32). Generation Bio had a negative return on equity of 91.07% and a negative net margin of 341.12%.The business had revenue of $0.77 million for the quarter, compared to analyst estimates of $2.51 million. Analysts expect that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on GBIO. Needham & Company LLC reissued a “buy” rating and set a $15.00 target price on shares of Generation Bio in a research note on Wednesday, August 13th. Wedbush downgraded Generation Bio from an “outperform” rating to a “neutral” rating and set a $7.00 target price for the company. in a report on Wednesday, August 13th. Canaccord Genuity Group boosted their target price on Generation Bio from $9.00 to $10.00 and gave the company a “buy” rating in a report on Monday, August 18th. Finally, Wall Street Zen downgraded Generation Bio from a “hold” rating to a “sell” rating in a report on Saturday, July 26th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.67.

Institutional Trading of Generation Bio

Several large investors have recently modified their holdings of GBIO. Squarepoint Ops LLC acquired a new position in Generation Bio in the fourth quarter worth approximately $70,000. Integrated Wealth Concepts LLC acquired a new stake in Generation Bio during the 4th quarter valued at $77,000. Aegis Wealth Management LLC acquired a new stake in Generation Bio during the 4th quarter valued at $94,000. AQR Capital Management LLC acquired a new stake in Generation Bio during the 1st quarter valued at $36,000. Finally, Millennium Management LLC acquired a new stake in Generation Bio during the 4th quarter valued at $97,000. 95.22% of the stock is currently owned by institutional investors and hedge funds.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.